Entero Therapeutics, INC

GridAI Technologies Corp. has entered into a material definitive agreement, providing a $2,000,000 secured convertible promissory note to Pronghorn Resources, LLC.

GridAI Technologies Corp. files an amendment to its Form 8-K to correct share and warrant allocations in a private placement raising approximately $8.5 million.

GridAI Technologies Corp. announced a private placement of common stock and warrants, raising approximately $8.5 million to fund general corporate purposes.

GridAI Technologies Corp. has entered into a Debt Settlement and Subscription Agreement to resolve a $1,032,315 debt obligation through an $800,000 cash payment and the issuance of 71,482 shares of common stock.

GridAI Technologies Corp. announced the closing of two private placement financings, raising approximately $2.54 million and $5.25 million respectively, to fund general corporate purposes.

GridAI Technologies Corp. has successfully regained compliance with Nasdaq's periodic financial reporting requirements after filing its 2025 annual report.

GridAI Technologies Corp. reports a net loss of $3.44 million for Q1 2026, with revenue generated from its new AI energy segment.

Entero Therapeutics reported significantly reduced net losses and increased cash, driven by lower operating expenses and a strategic acquisition of AI-driven energy platform Grid AI, while facing ongoing Nasdaq listing compliance challenges and divesting its IMGX subsidiary.

Entero Therapeutics reported significantly reduced net losses and improved cash burn in Q2 2025, but faces substantial doubt about its ability to continue as a going concern amidst critically low cash reserves and ongoing Nasdaq compliance issues.

Entero Therapeutics reports a net loss for Q1 2025 while navigating strategic changes, including a rescission agreement for the ImmunogenX merger and ongoing efforts to address Nasdaq listing requirements.

Entero Therapeutics reports a net loss of $2.6 million for Q3 2024 and is exploring strategic alternatives due to substantial doubt about its ability to continue as a going concern.

Entero Therapeutics' Q2 2024 report reveals a net loss of $3.2 million, a strategic shift involving the disposal of ImmunogenX assets, and substantial doubt about the company's ability to continue as a going concern.

GridAI Technologies Corp. reports a major strategic pivot to AI-driven energy orchestration following the acquisition of Grid AI Corp. and the rescission of its ImmunogenX subsidiary.

Entero Therapeutics reports ongoing losses and explores strategic alternatives, including a potential rescission agreement with ImmunogenX, raising concerns about its ability to continue as a going concern.

Entero Therapeutics' 10-K filing reveals significant operating losses and strategic realignments, raising substantial doubt about its ability to continue as a going concern.

First Wave BioPharma's 10-K filing outlines its capital stock structure, including common and preferred shares, and details recent transactions such as the ImmunogenX merger and a registered direct offering.

GridAI Technologies Corp. CEO Jason Sawyer reports vesting of 500,000 restricted stock units.

Director Jack Syage was granted 40,000 restricted stock units in GridAI Technologies Corp. which vested immediately on January 1, 2026.

GridAI Technologies Corp. Director Edward Borkowski was granted 40,000 restricted stock units, increasing his beneficial ownership to 60,248 shares.

GridAI Technologies Corp. Director Manpreet Uppal received a grant of 40,000 restricted stock units, which vested immediately.

GridAI Technologies Corp. Director Geordan Garrett Pursglove was granted 40,000 immediately vested restricted stock units.

GridAI Technologies Corp.'s CEO, Jason David Sawyer, was granted 40,000 restricted stock units that vested immediately on December 22, 2025.

Entero Therapeutics, Inc. is seeking shareholder approval for a reverse stock split to address Nasdaq's minimum bid price requirement, alongside proposals for director elections, executive compensation, and auditor ratification at its upcoming virtual Annual Meeting on June 30, 2025.

Entero Therapeutics finalizes its merger with ImmunogenX and provides pro forma financial statements reflecting the combined operations.

First Wave BioPharma finalizes the acquisition of ImmunogenX in an all-stock transaction, gaining a Phase 3-ready asset, latiglutenase, for celiac disease and strengthening its GI-focused pipeline.

First Wave BioPharma finalizes the acquisition of ImmunogenX in an all-stock transaction, adding latiglutenase, a promising celiac disease treatment, to its late-stage GI-focused clinical pipeline.

GridAI Technologies Corp. has entered into a Securities Purchase Agreement to sell approximately $5.25 million of its shares and warrants to various purchasers.

GridAI Technologies Corp. has filed an S-1/A amendment to register for resale up to 9,908,766 shares of its common stock by selling stockholders.

Entero Therapeutics files S-1/A for resale of 4.9M shares, rescinds ImmunogenX merger to focus on Adrulipase development, and faces significant financial and Nasdaq compliance challenges.

Entero Therapeutics files an S-1 registration statement for the resale of 4.9M common shares, signaling a strategic pivot to its Adrulipase program while navigating significant financial challenges and Nasdaq compliance issues.

Entero Therapeutics, Inc. is seeking to raise approximately $4 million through a public offering of common stock and pre-funded warrants to fund operations and advance its lead drug candidate, Adrulipase, while navigating severe financial constraints and the rescission of a recent merger.

Entero Therapeutics, Inc. is offering 12 million shares of common stock or pre-funded warrants to raise approximately $6 million, primarily to fund its lead drug candidate Adrulipase and address significant financial liabilities, while also unwinding a recent merger with ImmunogenX, Inc.

GridAI Technologies Corp. CEO Jason David Sawyer has reported beneficial ownership of 540,000 shares, representing 7.1% of the company's common stock, acquired through restricted stock units.

Arif Nasir Ali and affiliated entities have filed an amended Schedule 13D, indicating a reduction in their beneficial ownership of Entero Therapeutics, Inc. common stock to below the 5% reporting threshold following a recent share sale.

Arif Nasir Ali and affiliated entities have disclosed a combined beneficial ownership of approximately 5.26% of Entero Therapeutics, Inc.'s common stock, acquired for investment purposes.

Renaissance Technologies LLC and its parent company have reported a beneficial ownership of 0.92% in GridAI Technologies Corp. common stock.

Strategic EP, LLC and Alexander Chase Deitch have jointly reported a 5.0% beneficial ownership stake in GridAI Technologies Corp., totaling 209,541 shares of common stock.

Renaissance Technologies LLC and its parent company have reported a passive 5.44% ownership stake in Entero Therapeutics, Inc.